These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 28416758)
1. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758 [TBL] [Abstract][Full Text] [Related]
2. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Dasmahapatra G; Patel H; Friedberg J; Quayle SN; Jones SS; Grant S Mol Cancer Ther; 2014 Dec; 13(12):2886-97. PubMed ID: 25239935 [TBL] [Abstract][Full Text] [Related]
4. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967 [TBL] [Abstract][Full Text] [Related]
5. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854 [TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992 [TBL] [Abstract][Full Text] [Related]
7. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681 [TBL] [Abstract][Full Text] [Related]
8. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595 [TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related]
10. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293 [TBL] [Abstract][Full Text] [Related]
12. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224 [TBL] [Abstract][Full Text] [Related]
14. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836 [TBL] [Abstract][Full Text] [Related]
15. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Stehle A; Hugle M; Fulda S Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079 [TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933 [TBL] [Abstract][Full Text] [Related]
17. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. Wissing MD; Mendonca J; Kortenhorst MS; Kaelber NS; Gonzalez M; Kim E; Hammers H; van Diest PJ; Carducci MA; Kachhap SK FASEB J; 2013 Oct; 27(10):4279-93. PubMed ID: 23884428 [TBL] [Abstract][Full Text] [Related]
18. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754 [TBL] [Abstract][Full Text] [Related]
20. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]